Company Filing History:
Years Active: 2014-2018
Title: An Overview of Inventor Sarat C. Chattaraj
Introduction
Sarat C. Chattaraj, based in Morgantown, West Virginia, is an accomplished inventor with a strong portfolio of five patents to his name. His innovative contributions primarily lie in the pharmaceutical field, where he has focused on improving drug formulations and bioavailability.
Latest Patents
Among his notable inventions is a fenofibrate formulation that includes various dosage forms comprising a plurality of beads or particles. This formulation features a pharmaceutical composition containing fenofibrate, a specific mass ratio of the drug to a water-soluble binder, and includes surfactants intended to enhance the overall efficacy. The innovation claims a first Cmax in vivo that is significantly higher compared to other comparative formulations.
Chattaraj has also developed stable pharmaceutical dosage forms that include carbidopa, levodopa, and entacapone. These dosage forms are distinguished by their preparation method that involves mixing the three compounds and forming granules, which may include starch and microcrystalline cellulose as excipients. This work aims to provide a dosage form with bioavailability comparable to the traditional separate addition of carbidopa, levodopa, and entacapone.
Career Highlights
Sarat C. Chattaraj currently works with Mylan GmbH, a leading global generic and specialty pharmaceuticals company. His expertise in pharmaceutical formulations and drug delivery systems has made significant contributions to the development of innovative medications that improve patient care.
Collaborations
Chattaraj collaborates with esteemed colleagues such as Glenn Allen Redelman and Andrew Alan Shaw. Their combined efforts have facilitated advancements in pharmaceutical sciences, leveraging their diverse expertise to enhance the quality and efficiency of drug formulations.
Conclusion
Sarat C. Chattaraj exemplifies dedication and innovation in the pharmaceutical industry. His patents are a testament to his commitment to improving drug formulations, ultimately leading to better therapeutic outcomes for patients. With a strong foundation at Mylan GmbH, Chattaraj continues to be a valuable asset in the field of pharmaceutical research and development.